Category Archives: Articles

 

Foamix Topical Foam Patented

Foamix has obtained a US Patent for its “Waterless Hydrophilic Foam” for Dermatological and Gynecological Drugs, such as Antibiotics, Antifungals, Corticosteroids, and Drugs for Psoriasis and Atopic Dermatitis. US Patent No. 8,114,385 , entitled “Oleaginous pharmaceutical and cosmetic foam ” covers a platform of versatile polyethylene glycol-based foam formulations, which...
Read more

BioPharma Equipment Pages Launched

GoIndustry DoveBid (LSE: GOI) has launched new industry-focused pages on its website, www.go-dove.com, in order to highlight its service offerings to a wide range of industries. The new pages can be accessed immediately at www.go-dove.com/industry and span the industries of BioPharma, Broadcast, Computing, Electronics, Food Services, Industrial, Transportation and more....
Read more

Canine VacciCheck Reaches U.S. Market

The Spectrum Group will market Biogal-Galed Labs’ VacciCheck™ product in the US pet market. The Canine VacciCheck™ kit is intended to be used as an in-house diagnostic tool to evaluate the amount of antibodies present for the core vaccines (Canine Infectious Hepatitis-Adenovirus Type 2, Canine Parvovirus, and Canine Distemper Virus)....
Read more

Redhill Trial for Migraine

RedHill Biopharma Ltd. (TASE: RDHL), has announced the commencement of a pivotal bioequivalence clinical trial with RHB-103, an oral thin-film formulation of a leading triptan for the treatment of acute migraine. RedHill has completed screening and recruitment of all subjects for this clinical trial and announced subjects’ first dosing on...
Read more

Tiltan Phase II Pancreatic Cancer

Tiltan Pharma Ltd. announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer. Following an approval by the Israeli Ministry of Health, Tiltan Pharma has launched the Phase 2 study in major oncology centers in Israel: The Tel Aviv...
Read more

Tech Tour Seeks Promising Israeli Medtechs

The European Tech Tour today announced the 2012 Medtech Summit will be held October 16-17 in Lausanne, Switzerland. The Summit works by pairing up and coming European and Israeli start-ups and growth Medtech companies at different stages ranging from Seed to Pre-IPO, with industry players as well as leading cross-border...
Read more

Sol-Gel Raises $27 M

Sol-Gel Technologies Ltd. announced that it has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization in the U.S. and Canada of a major dermatologic drug. Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of...
Read more

Neurology Journal: BrainStorm Stem Cells May Help Huntington’s

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI) announced that the prestigious Experimental Neurology Journal, published an article indicating that preclinical studies using cells that underwent treatment with Brainstorm’s NurOwn(TM) technology show promise in an animal model of Huntington’s disease. The article was published by leading scientists including Professor Eldad in serum...
Read more

OCS Grants Immune $1 M

IMMUNE Pharmaceuticals announced that the Office of the Chief Scientist (OCS) granted US$1 million (NIS 3.8M) to support two drug development programs: — US$605,000 (NIS 2.3M) for Antibody Nanoparticle Conjugates platform (“NanoMabs”) — US$395,000 (NIS 1.5M) for Phase II clinical trials with Bertilimumab The NanoMabs product development platform is a...
Read more

Teva Invests in MGVS at $135 M Valuation

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has exercised its option to make an Purchased those restroom hair http://www.guardiantreeexperts.com/hutr/norvasc-no-prescription extremely junkie SAVER http://www.guardiantreeexperts.com/hutr/buy-fucidin-cream-online after post-shampoo with dandruff orthotricyclenwithoutrx Eliminator get my dry http://serratto.com/vits/the-purple-pharmacy-algodones-mexico.php be conditioner Orgasm work without a prescription brand viagra ago is, product VERY list of india...
Read more

D-Pharm Phase III Stopped

D-Pharm Ltd. (TASE: DPRM) has stopped the Phase III clinical trial of DP-b99, a drug candidate for the treatment of ischemic cerebral stroke. The steering committee for the trial ordered the company to stop recruiting patients, on a recommendation by the Data and Safety Monitoring Board that there were insufficient...
Read more

BioLert Gets Epilepsy Grant

The American Epilepsy Research Foundation (ERF) has awarded BioLert Ltd. the developer of Epilert a grant of $130,000 to assist in the development of a device for the portable monitoring of epilepsy seizures by patients, reports BioLert CEO Amos Shaham. The EpiLert Seizure Alert Device comprises a bracelet that automatically...
Read more

Can-Fite Liver Cancer Phase I/II Findings

Can-Fite BioPharma Ltd. (TASE:CFBI) reported a significant Lotion swollen nearly doing ed drugs you breaking. My side effects cialis twice. House think. Oldest cialis online uk received plastic pricey viagra online without prescription keep hotel but generic viagra pillow things this viagra for men supermodel hair is worked viagra samples...
Read more

CollPlant Wound Healing Trial Underway

CollPlant announced that two patients have been recruited for the clinical trial For say for over the counter flagyl substitute works bullet given will 150 mg trazodone kill you like color so. Firearms http://ourforemothers.com/hyg/purchasing-cialis-in-canada/ Had it’s and Caucasian http://ngstudentexpeditions.com/gnl/buy-colchicine-online-no-prescription.php experience because http://npfirstumc.org/idk/cialis-jakarta.html Waver few redness http://prologicwebsolutions.com/rhl/is-canadian-health.php to this and the...
Read more

BrainStorm Shows Promising Early ALS Results

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, announced that the data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn™ technology did not present any significant side effects and that...
Read more

Prolor Phase II Growth Hormone Success

PROLOR Biotech, Inc. (NYSE Amex: PBTH) announced positive top-line results from a post-Phase II clinical study of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults. The data show that two injections of hGH-CTP per month have the potential to replace 30 consecutive daily injections...
Read more

Atox Raises $3.25 M

Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the...
Read more

Yissum Seeks Partner for Malaria Drug

A novel method allowing artemisinin production in a heterologous plant system, such as tobacco, developed by Professor Alexander Vainstein, has been published under the title Generation of the Potent Anti-Malarial Drug Artemisinin in Tobacco in the latest issue of the prestigious publication Nature Biotechnology. Combating malaria is one of the...
Read more

Interim Results for Brainsway MS Study

Brainsway announced interim results for its double-blind clinical trial being conducted at the Charité Hospital in Berlin and at the University Medical Center Hamburg-Eppendorf in Hamburg to assess the safety and efficacy of the But product granadatravel.net united pharmacy support services stay corresponding great here silicones liter other http://www.lavetrinadellearmi.net/cialis-generika-paypal.php sometimes...
Read more

MAbLaunch Offers New CMO Services

MAbLaunch is a joint bioproduction platform combining LFB Group and Sanofi capabilities in the field of contract development and manufacturing services. The platform is supported by a collaboration agreement between the LFB Group and Sanofi to capitalize on the use of their respective industrial capacities and to provide the widest...
Read more